Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Masahiro, Kamata"'
Autor:
Makoto Ito, Masahiro Kamata, Hideaki Uchida, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 6, Iss 5, Pp 168-171 (2023)
Abstract Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupil
Externí odkaz:
https://doaj.org/article/4b139843692745c887fbbfb2d450e943
Autor:
Makoto Ito, Masahiro Kamata, Takeko Ishikawa, Hideaki Uchida, Shoya Suzuki, Ryosuke Takeshima, Ayu Watanabe, Itsumi Mizukawa, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 6, Iss 5, Pp 152-158 (2023)
Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medica
Externí odkaz:
https://doaj.org/article/bf8f9473143e4fcba7849cbbc62924ca
Autor:
Masahiro Kamata, Yayoi Tada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
In the past, psoriasis was considered a skin disease caused only by keratinocyte disorders. However, the efficacy of immunosuppressive drugs and biologics used to treat psoriasis proves that psoriasis is an immune-mediated disease. Indeed, a variety
Externí odkaz:
https://doaj.org/article/dd77b48dfbac4508865896f274505c07
Autor:
Masahiro Kamata, Yayoi Tada
Publikováno v:
JID Innovations, Vol 3, Iss 3, Pp 100195- (2023)
Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can
Externí odkaz:
https://doaj.org/article/3def8078a9a348b08b547b7e2914d036
Autor:
Hideaki Uchida, Masahiro Kamata, Shota Egawa, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 5, Iss 1, Pp 17-21 (2022)
Abstract Dupilumab demonstrated high efficacy and tolerable safety profiles in moderate‐to‐severe atopic dermatitis (AD) patients in clinical trials; however, certain patients suffer from facial redness, while obtaining good responses on the trun
Externí odkaz:
https://doaj.org/article/4ff8145c25d9420e8d0dbf8c5954eff7
Autor:
Masahiro Kamata, Yayoi Tada
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. This disease impairs patients’ quality of life enormously. Pathological findings demonstrate proliferation and abnormal differentiation of keratinocytes and
Externí odkaz:
https://doaj.org/article/2765848fb0fc4aec805ae51b4512142e
Autor:
Hideaki Uchida, Masahiro Kamata, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Kenjiro Mitsuhashi, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 4, Iss 5, Pp 143-145 (2021)
This case report describes a 44‐year‐old male patient with atopic dermatitis who developed malignant lymphoma (diffuse large B‐cell lymphoma) during the dupilumab treatment.
Externí odkaz:
https://doaj.org/article/fb071134a39642af923025fe7e044258
Publikováno v:
Acta Dermato-Venereologica, Vol 101, Iss 10 (2021)
Abstract is missing (Short communication)
Externí odkaz:
https://doaj.org/article/18958e1cf8204464a54d81ceb54ad703
Autor:
Masahiro Kamata, Yayoi Tada
Publikováno v:
JID Innovations, Vol 1, Iss 3, Pp 100042- (2021)
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by recurrent eczema with exacerbations and remissions. AD impairs patients’ QOL and places a heavy burden on patients. Recently, dupilumab, an anti–IL-4Rα
Externí odkaz:
https://doaj.org/article/07047c7716774b8584c26daddda0a67a
Autor:
Ayu Watanabe, Masahiro Kamata, Mayumi Nagata, Kotaro Hayashi, Ryo Hidaka, Kenta Matsuda, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 3, Iss 3, Pp 68-70 (2020)
Externí odkaz:
https://doaj.org/article/6b21d12df4a1469bb3242a38bf38ca65